Cannabis and the Teenage Brain: New Research Reveals Why Cognitive Effects Are Not One-Size-Fits-All

The editorial’s synthesis of nine studies arrives at a moment when the scientific community is recalibrating its assumptions about cannabis and the developing brain. For much of the past two decades, the dominant narrative in adolescent cannabis research was one of broad, generalized harm, an expectation rooted in the well-documented protracted maturation of prefrontal and temporal brain regions through the mid-twenties. What this Research Topic makes clear is that the reality is considerably more textured. Neurocognitive outcomes following cannabis use are neither uniform nor inevitable; they emerge from an interplay between the individual’s biological makeup, the specific characteristics of their cannabis consumption, the social contexts in which use occurs, and the developmental stage at which exposure begins. This shift from a monolithic harm model toward a more differentiated, mechanistic understanding carries practical consequences for how clinicians, educators, and policymakers approach prevention and intervention.

One of the most consequential methodological themes running through the collection is the distinction between risk factors and consequences. Cross-sectional designs, which compare current users with non-users at a single point in time, cannot resolve whether observed differences in brain function or cognition preceded the onset of use or resulted from it. This is not a trivial ambiguity. Pre-existing differences in inhibitory control, reward sensitivity, or emotion regulation could plausibly predispose adolescents toward earlier or heavier cannabis use, a phenomenon sometimes described as neurodevelopmental vulnerability. Alternatively, repeated exposure to tetrahydrocannabinol, the primary psychoactive constituent of cannabis, could produce lasting alterations in the very circuits that support these capacities. The editorial’s emphasis on longitudinal designs reflects a growing consensus that only prospective measurement, ideally beginning before the onset of use, can adjudicate between these competing explanations. The study by Viera Perez and colleagues exemplifies this approach: by demonstrating that blunted striatal response to reward predicted subsequent substance use through increased impulsivity roughly a year later, the findings suggest that atypical reward processing may function as a developmental antecedent rather than a downstream consequence, at least for early stages of use.

The striatum’s role in this pathway deserves particular attention. This region, central to the brain’s reward circuitry, undergoes substantial functional reorganization during adolescence as dopaminergic innervation matures. A blunted neural response to monetary incentives in early adolescence could reflect a reduced sensitivity to conventional rewards, which in turn might heighten the appeal of substances that produce more pronounced neurochemical stimulation. If this interpretation holds, it reframes prevention efforts: rather than targeting cannabis use directly, interventions might aim to strengthen reward responsiveness to prosocial activities or to bolster self-regulatory capacities that buffer against impulsive decision-making. The editorial’s suggestion that interventions targeting reward processing and self-regulation could mitigate vulnerability is consistent with a broader movement in developmental neuroscience toward treating cognitive control as a modifiable target rather than a fixed trait.

Equally instructive is the evidence on abstinence and recovery. The randomized clinical trial by Schuster and colleagues, which used contingency management to sustain four weeks of abstinence among adolescents, represents a methodological advance over observational studies of self-selected quitters. Contingency management, which provides tangible reinforcement for verified abstinence, is among the most robustly supported behavioral interventions in the addiction field, and its application here allowed the researchers to separate the effects of abstinence itself from the motivational characteristics of adolescents who spontaneously stop using. The observation that maintained abstinence was associated with faster reaction times on the Stop Signal Task, a well-validated index of inhibitory control, suggests that at least some cannabis-related cognitive changes are not permanent. This finding aligns with a small but growing literature indicating partial normalization of cognitive performance and neural function after sustained abstinence, though the duration required for full recovery, and whether recovery is complete for all cognitive domains, remains unresolved. For clinicians, the practical implication is that cognitive improvement may be an early and observable benefit of cessation, potentially useful as motivational feedback in treatment settings.

The moderating role of individual differences emerges as perhaps the most scientifically generative theme in the collection. The finding by Wallace and colleagues that circulating endocannabinoid levels differentially predict memory outcomes among heavy users points toward a biomarker-based understanding of cannabis-related risk. The endocannabinoid system, comprising lipid-derived signaling molecules such as 2-arachidonoil-glicerol and N-arachidonoylethanolamine, is the primary neurochemical target of tetrahydrocannabinol and plays a fundamental role in regulating synaptic transmission, stress responses, and reward learning. Chronic exogenous cannabinoid exposure can downregulate cannabinoid receptor availability, and baseline variation in endogenous signaling may determine how strongly this disruption manifests cognitively. If higher 2-AG levels genuinely buffer against verbal memory deficits while elevated AEA accompanies worse performance, then peripheral endocannabinoid profiling could eventually help identify adolescents at heightened neurocognitive risk before substantial harm accrues. Such an approach would need considerable validation, including demonstration that peripheral levels reliably reflect central nervous system signaling, but the conceptual framework it opens is significant.

Sex differences constitute another moderating dimension with substantial implications. The finding by Baacke and colleagues that network topology varied by sex, particularly among males with greater past-year use and earlier initiation, echoes a broader pattern in the addiction literature in which males and females show partially distinct neurobiological responses to cannabis. Adolescent females, on average, progress from initial use to cannabis use disorder more rapidly than males, a phenomenon sometimes termed the telescoping effect, while males may show stronger associations between use frequency and structural brain outcomes. The observation that resting-state network metrics, which capture the coordinated activity of large-scale brain systems during wakeful rest, are differentially sensitive to cannabis exposure in males underscores that aggregate analyses pooling both sexes may obscure meaningful heterogeneity. Future studies powered to detect sex-specific effects will be essential for translating this research into sex-informed clinical guidance.

The co-occurrence of cannabis use with other substances presents a persistent interpretive challenge that the editorial rightly flags. Alcohol and nicotine are the most common companions of adolescent cannabis use, and each carries its own neurocognitive burden. Disentangling the unique contribution of cannabis from that of polysubstance exposure requires either sufficiently large samples with careful statistical control or, ideally, samples of adolescents who use cannabis in relative isolation. Similarly, the variability in how studies operationalize cannabis use, ranging from binary ever-use classifications to detailed indices of frequency, quantity, and potency, limits comparability across the literature. The rising potency of cannabis products and the proliferation of alternative routes of administration, including vaporized concentrates and edible formulations, further complicate efforts to generalize findings from earlier cohorts, whose exposure profiles differed substantially from those of adolescents today. Dose and potency information, when available, enables more precise exposure characterization and may reveal threshold effects that binary classifications conceal.

The acute administration study by Paige and colleagues adds a complementary experimental perspective that observational designs cannot provide. By administering tetrahydrocannabinol under double-blind conditions and measuring its immediate cognitive effects, the researchers could establish that the drug itself disrupts neurocognitive performance in the moment, independent of the pre-existing differences that confound observational comparisons. The finding that disruption was more pronounced among individuals with limited use history and stronger subjective drug effects is consistent with pharmacological tolerance, the adaptive process by which repeated exposure attenuates both subjective and cognitive responses to a drug. Tolerance has a double-edged significance: it may reduce the acute impairment experienced by regular users, but it also reflects neuroadaptation that could underlie longer-term alterations in endocannabinoid signaling. Understanding how acute sensitivity relates to chronic vulnerability remains an open question with direct relevance to harm reduction messaging.

The intersection of cannabis research with clinical populations, illustrated by the findings among young adults with HIV, broadens the relevance of this work beyond typically developing adolescents. Chronic neuroinflammation, a hallmark of both HIV infection and heavy cannabis exposure, may interact in complex ways, and the suggestion that mild-to-moderate use showed patterns consistent with cognitive benefit in this population, possibly through anti-inflammatory mechanisms, warrants careful and cautious investigation. Cannabinoids possess documented immunomodulatory properties, and while therapeutic applications remain speculative in this context, the findings caution against assuming that cannabis effects are uniformly detrimental across all populations and all doses. At the same time, the association between heavier use and poorer performance across multiple cognitive domains in the broader sample reinforces the dose-dependence that characterizes much of this literature.

The identification of specific emotion regulation domains, rather than global emotion dysregulation, as most affected among youth who use cannabis refines the conceptualization of affective risk. Impulse control, goal-directed behavior, and nonacceptance of emotional experience are each dissociable constructs with distinct neural substrates, and their differential prevalence suggests that cannabis-related affective difficulties are not diffuse but patterned. This specificity matters for intervention design: programs targeting emotional awareness and acceptance may address different mechanisms than those targeting impulse control, and matching intervention components to the most affected domains could improve efficacy. The connection to hazardous use over twelve months, mediated partly by lower resistance to peer influence, further illustrates how cognitive and social factors converge to shape trajectories of use, suggesting that peer-context interventions and executive function support may operate on complementary pathways.

Taken together, the studies assembled in this Research Topic chart a course for the next phase of adolescent cannabis research. Priorities include larger and more diverse longitudinal cohorts that begin before the onset of use, standardized and detailed measurement of cannabis exposure including potency and mode of administration, systematic examination of sex and other biological moderators, integration of peripheral biomarkers with neuroimaging phenotypes, and deliberate attention to polysubstance co-use. The movement toward mechanistic and personalized approaches reflected in this collection signals a maturing field, one increasingly capable of distinguishing which adolescents face elevated neurocognitive risk, through which pathways that risk operates, and at which points intervention might alter the trajectory. For a substance that remains the most widely used illicit drug globally among adolescents, and one whose potency and availability continue to rise, such precision is not an academic luxury but a public health necessity.

Subject of Research: Editorial: Cannabis use and neurocognitive functioning in adolescents

Article Title: Editorial: Cannabis use and neurocognitive functioning in adolescents

Article References: Cservenka, A., & Jacobus, J. (2026). Editorial: Cannabis use and neurocognitive functioning in adolescents. Frontiers in Adolescent Medicine, 4, Article 1852157. https://doi.org/10.3389/fradm.2026.1852157

Image Credits: AI Generated

DOI: 10.3389/fradm.2026.1852157

Keywords: Editorial, Cannabis, neurocognitive, functioning, adolescents, scientific research